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Abstract 
Purpose: Antibiotics are one possible treatment for patients with recurrent acute throat infections (ATI), but effec‑
tiveness can be modest. In view of worries over antibiotic resistance, treatment pathways that reduce recurrence of 
ATI are essential from a public health perspective. Integrative treatment strategies can be an option but there is still a 
high demand to provide evidence of their cost effectiveness.
Methods: We constructed a 4‑state Markov model to compare the cost‑effectiveness of SilAtro‑5‑90 as adjuvant 
homeopathic therapy to care as usual with care as usual alone in reducing the recurrence of ATI for children and 
adults with suspected moderate recurrent tonsillitis. The analysis was performed from a societal perspective in Ger‑
many over a 2‑year period. Results are reported separately for children < 12 and for individuals aged 12 and over. The 
model draws on evidence from a multi‑centre randomised clinical trial that found this strategy effective in reducing 
recurrence of ATI. Costs in 2019 € and outcomes after 1 year are discounted at a rate of 3% per annum.
Results: For adults and adolescents aged 12 years and over, incremental cost per ATI averted in the adjuvant therapy 
group was €156.64. If individuals enter the model on average with a history of 3.33 previous ATIs, adjuvant therapy has 
both lower costs and better outcomes than care as usual. For children (< 12 years) adjuvant therapy had both lower 
costs and ATI than care as usual. The economic case is stronger if adjuvant treatment reduces surgical referral. At a 
hypothetical cost per ATI averted threshold of €1000 probabilistic sensitivity analysis suggests Silatro‑5‑90 has a 65% 
(adults) and 71% (children) chance of being cost‑effective.
Conclusion: Our results indicate the importance of considering homeopathy as adjuvant therapy in the treatment of 
ATIs in individuals with recurrent tonsillitis from a socio‑economic perspective. Further evaluation should assess how 
differences in uptake and sustained use of homeopathic adjuvant therapy, as well as changing patterns of antibiotic 
prescribing, impact on cost effectiveness.
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Introduction
Respiratory tract infections (RTIs) are quite common rea-
sons to consult a general practitioner (GP) and accord-
ing to epidemiological data account for 75% of antibiotic 
prescriptions written in the US [1, 2]. Tonsillitis is one 
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major category of RTIs that is indicated by a swelling and 
inflammation of the pharyngeal tonsils and the back of 
the throat, including the adenoids and the lingual ton-
sils. Other signs and symptoms of tonsillitis include a 
sore throat and difficulty in swallowing. In acute tonsil-
litis, which is mostly of viral origin, infections may ini-
tially respond to symptomatic drugs (e.g., analgesics) and 
antibiotic therapy but may return episodically leading to 
a diagnosis of recurrent tonsillitis [2]. In both acute and 
recurrent tonsillitis, health professionals are conscious 
of the risks of antimicrobial resistance (AMR) that can 
result from excess use of antibiotics. In order to cope 
with AMR, a “no antibiotics” or a “delayed antibiotics” 
strategy is suggested, while taking specific clinical criteria 
into account [3, 4].
When applying this strategy, the use of homeopathic 
remedies could be part of the solution [5]. Homeopa-
thy was developed by the German physician Samuel 
Hahnemann 200 years ago. It is based on ‘the principles 
of similars’ and ‘like cures like’ saying that diluted and 
potentized substances that cause symptoms in healthy 
individuals are used to treat patients with similar symp-
toms [6]. Homeopathy is geographically widespread and 
is the fourth most frequently used complementary and 
alternative medicine (CAM) therapy [7]. Advantages of 
this therapy, explaining its popularity, may include fewer 
and less serious side effects [8, 9].
Any treatment strategy that may help reduce the need 
for antibiotic use potentially is of great public health 
interest and help to face the growing threat of AMR [10]. 
The reduction of acute throat infections (ATI) and the 
need for medication may also have an impact on resource 
use and costs within health systems and for society. It 
could mean less time out of education and work.
Some studies have shown the effectiveness of homeo-
pathic treatment for patients with these conditions. In 
an early study, Wiesenauer reported positive results 
in symptom reduction in an observational study of 107 
patients that were treated homeopathically without anti-
biotics [11]. In another randomised, double-blind, pla-
cebo-controlled, 6-day pilot study in 30 children in South 
Africa, the homeopathic group had a statistically signifi-
cant reduction in pain, inflammation of the pharynx and 
tonsil size [12]. However, the evidence to date has been 
equivocal with a recent meta-analysis of 8 trials com-
paring oral homeopathic treatment as an alternative to 
either placebo or standard treatment to prevent or treat 
RTIs in children reporting limited benefits [13]. How-
ever, according to a recent narrative review on the con-
tribution of Integrative Medicine to reduce antibiotic use 
there is a high demand to evaluate integrative treatment 
strategies that may contribute to reducing antibiotic use 
and to providing evidence of their cost-effectiveness [14].
In this study, we consider the use of homeopathic med-
icine as an adjuvant rather than as an alternative treat-
ment for recurrent throat infections. For example, a 
recent randomised controlled trial reported significantly 
better outcomes for adjuvant homeopathic therapy in 
the treatment of pre-adolescent children with upper res-
piratory tract infections and fever [15]. Another promis-
ing intervention that has been used for the treatment of 
patients aged 6–60 experiencing tonsillitis is the com-
plex homeopathic medicine SilAtro-5-90. A multicentre 
randomised clinical trial of patients experiencing recur-
rent tonsillitis found that the risk of having an ATI was 
significantly lower in patients treated with conventional 
symptomatic medication together with SilAtro-5-90 
(intervention group) than in those treated with conven-
tional symptomatic medication alone (usual care group). 
At the same time, the adjuvant SilAtro-5-90 plus usual 
care group had a significantly reduced use of antibiotic 
medication, and a lower number of days absent from 
work or school when experiencing an ATI [16].
Based on these findings, the authors suggested further 
research to investigate the possible cost-effectiveness 
of SilAtro-5-90 in the treatment of recurrent tonsillitis. 
This paper thus explores whether adjuvant homeopathic 
medicinal treatment with SilAtro-5-90 alongside usual 
care in the treatment of recurrent tonsillitis is cost-effec-
tive by means of an economic modelling analysis (see 
Additional file 1 for a detailed description).
Method
Model overview and interventions
A 4-state Markov model has been constructed to assess 
the cost-effectiveness of SilAtro-5-90 as an adjuvant 
homeopathic therapy to care as usual compared with care 
as usual alone in reducing the recurrence of ATIs for a 
hypothetical population of children and adults with sus-
pected moderate recurrent tonsillitis in Germany over a 
2-year period. The primary outcome for the model is the 
incremental cost per ATI averted. Estimates of the recur-
rence of ATIs following intervention are drawn from an 
open-label multi-centre randomised controlled trial of 
SilAtro-5-90 [16] for individuals with moderate recurrent 
tonsillitis in 19 study centres across Germany, Spain and 
the Ukraine. Moderate recurrent tonsillitis was defined 
as experiencing at least 3 ATIs in the prior 12 months or 
2 ATIs in each of the previous 2 years.
In that study 256 individuals aged 6–60 were ran-
domised to SilAtro-5-90 plus usual care compared 
to usual care alone. The adjuvant intervention, SilA-
tro-5-90  (Tonsilotren®, Deutsche Homöopathie-Union, 
DHU-Arzneimittel GmbH & Co., KG), is a complex 
homeopathic medicinal product containing 5 active 
ingredients in different potencies (from D2 to D8 with D2 
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corresponding to a 1:102 and D8 a 1:108 dilution). While 
Atropinum sulfuricum (D5) and Mercurius bijodatus 
(D8) are well proven to treat the acute phase of the tonsil-
litis with typical symptoms such as dark red throat and 
difficulties in swallowing, and Hepar sulfuris (D3) is help-
ful in the treatment of impending suppuration, Kalium 
bichromicum (D4) is more used for subacute course of 
inflammation with thick yellowish discharges [17, 18]. 
The final active ingredient Silicea (D2) is a commonly 
used homeopathic remedy in the treatment of chronic 
diseases, which stimulates the regeneration of tissues 
and thus improves healing in chronic processes [17]. In 
the trial, there were 3 treatment periods, each of 8 weeks, 
spread uniformly across the 12-month trial. After each 
period of treatment, there was an 8-week observation 
period without adjuvant therapy. Frontline usual care in 
the trial consisted of watchful waiting plus self-care with 
local throat antiseptics and/or anaesthetics (solution, loz-
enges). Antibiotic medication, typically Amoxicillin tab-
lets or liquids, and/or antipyretic and analgesic therapy 
for treatment of ATIs was prescribed by physicians for 
both adults and children as they deemed appropriate in 
both study groups. In addition to the physicians docu-
menting the number of ATIs, based on their diagnosis, 
and mean infection free time that occurred during the 
trial period, as well as frequency in the use of antibiotics, 
study participants also kept diaries where they recorded 
impacts on their daily activities. The trial reported that 
the number of patients without an episode of ATI was 
significantly greater in the adjuvant therapy group that 
in the usual care alone group, 67.2% versus 37.5% (p < 
0.0001). The hazard ratio for having at least one ATI in 
the adjuvant therapy group was 0.45 compared to the 
usual care alone group. There was also significantly less 
use of antibiotics to treat ATIs when they occurred in the 
adjuvant therapy versus the usual care alone group (37% 
vs 58.2%, p < 0.0008).
Model structure
We assumed that our Markov model would have 3 cycles 
per annum as in the effectiveness trial that we draw 
on there were 3 periods of active care of 8 weeks dura-
tion and 8 weeks subsequent observational follow up in 
12 months. We chose a 2-year-time frame for the model, 
given that 2 ATIs in 2 consecutive years is one definition 
of recurrent ATI, and this has implications for potential 
future use of expensive tonsillectomy surgery. However, 
we report results from a one-year time frame perspective 
as well in sensitivity analysis. Our model reflects typical 
usual care pathways in Germany. In Germany, adults or 
children with a history of ATIs do or do not present to 
their primary care doctor (GP) in case of an ATI and if 
they suspect that they may have a further potential ATI. 
In case of their presentation, the GP then takes a patient 
history and performs a Centor assessment for adults or a 
McIsaac-adjusted-Centor score for children [19]. In our 
model therefore we assume that where Centor scores 
are at their highest levels of 3 or 4, in Germany, indi-
viduals will either receive usual care alone (consisting of 
watchful waiting/self-care with antiseptics and/or anaes-
thetics, plus discretionary use of antibiotics and/or anal-
gesics/antipyretics for the treatment of ATIs) or they will 
receive a regimen of SilAtro-5-90 plus usual care (Fig. 1). 
The dosage regimens for adjuvant SilAtro-5-90 in each 
treatment cycle in the model are assumed to be the same 
as in the trial where each of the three 8-week active treat-
ment cycles, consisted of 1 tablet 3 times per day for chil-
dren (age 6 to < 12 years) and 2 tablets 3 times per day for 
adolescents and adults over 12 years. We assumed, as in 
the trial, that each 8 weeks treatment cycle would be fol-
lowed by an 8 weeks period where only usual care would 
be provided.
There are 4 possible transition states at the end of each 
cycle (Fig.  2). If there has been no ATI we assume that 
individuals may continue to self-medicate with SilA-
tro-5-90 as a preventive measure (as observed in the 
trial) in the next cycle, but with no further GP consulta-
tion. We assume that all individuals in both arms of the 
model who experience a recurrent ATI have a further GP 
consultation during each cycle in line with usual Ger-
man care and they may potentially be prescribed a course 
of antibiotics. In line with current recommendations 
in Germany [20] our Markov model also assumes that 
tonsillectomy surgery may be offered as an alternative 
treatment option to patients who have had a minimum 
of 4 repeat ATIs events. In our model, we conservatively 
assume that successful tonsillectomy surgery eliminates 
the ATIs and the individual no longer needs further treat-
ment. This is conservative as there can be a very small 
risk of reoperation. There is also a fourth death state, 
reflecting both general population mortality risk and the 
very small increased risk associated with tonsillectomy 
surgery. Mortality due directly to ATIs is extremely rare 
so we conservatively assume that there is no enhanced 
risk of mortality due to incidence of recurrent ATIs. We 
assume that these care pathways may continue into a sec-
ond year, given the model population’s previous history 
of recurrent ATIs, and also mindful that moderate recur-
rent ATI can be defined as 2 ATIs in 2 consecutive years.
Model parameters
Table  1 summarises parameters used in the model, 
assumptions on distributions used in probabilistic sen-
sitivity analysis and sources for data. All analyses were 
modelled, implemented and performed with TreeAge 
Pro decision modelling software [21]. Expected rates 
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of ATIs in the model for intervention and usual care 
groups were assumed to be the same as those reported 
in the multi-centre trial. The expected rate of ATI per 
cycle was assumed to be one third of the rate observed 
in the 12-month period. The likelihood of being treated 
with antibiotics following recurrent ATI is also assumed 
to be the same as that recorded in the trial. Where anti-
biotics are used, we assume, in line with typical German 
practice, that treatment lasts for 7  days, with a lower 
dosage for children (aged 6 to < 12  years) compared to 
adults and adolescents over 12  years. In line with the 
trial, we assume that patient age has no impact on the 
effectiveness of adjuvant therapy in reducing ATI rates. 
The mortality rate associated with tonsillectomy was 
based on registry data over 8 years in Sweden cover-
ing more than 82,500 procedures where just 2 deaths 
occurred [22]. Underlying 1-year both-sex probability of 
mortality was taken from German life tables for 2019 in 
the WHO’s Global Health Observatory Data Repository 
[23]. The probability of mortality per cycle was assumed 
to be one third of the annual mortality rate.
Our analysis is conducted from a societal perspec-
tive. This takes account of costs within the health care 
system to health insurers, as well as any out of pocket 
costs to patients for medications, and days out of normal 
daily role due to recurrent ATIs, either work for adults 
or school for children. Costs of SilAtro-5-90 were based 
on over the counter average prices reported in the trial 
in Germany where a month’s course of SilAtro-5-90 cost 
€13.45 for adults and €6.73 for children (2019 prices). 
Resource use and costs of tonsillectomy surgery are taken 
from German Diagnosis Related Groups (DRG) data [24]. 
The costs of antibiotic treatment are taken from the mean 
pharmacy price across different products; for adults a 
course of penicillin treatment is €13.09 and for children 
aged 6–12 years this is €12.41 including a dispensing fee 
for pharmacists of €5 for each course of antibiotics for 
adults. The cost of a GP consultation according to data 
Fig. 1 Excerpt of health economic model structure showing care pathways in real world practice in Germany starting with patients presenting to a 
primary care doctor (GP) with a potential acute throat infection (ATI)
Fig. 2 Structure of the Markov model showing the 4 possible 
transition states at the end of any cycle (ATI acute throat infection)
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Table 1 Model parameters












 SilAtro‑5‑90 costs per 
month (C)
€6.73 L: €3.37 – Fixed Palm et al.
U: €10.10
 SilAtro‑5‑90 costs per 
month (AA)
€13.45 L: €6.73 – Fixed Palm et al.
U: €20.18
 Tonsillectomy surgery 
(C)
€3495 L: €1748 – Fixed German Diagnosis 
Related Groups (DRG) 
data 2019
U: €5243
 Tonsillectomy surgery 
Adolescents and 
Adults (AA)
€2538 L: €1269 – Fixed German Diagnosis 
Related Groups (DRG) 
data 2019
U: €3807
 Antibiotics (1‑week 
course) (C)
€12.41 L: €6.21 – Fixed German pharmacy data 
2019U: €18.62
 Antibiotics (1‑week 
course) (AA)




€5 per item for adults – – Fixed German pharmacy data 
2019
 General practitioner 
(per consultation)
€28 L: €14 – Fixed Data from the Associa‑




 Daily productivity loss 
cost
€175.94 L: €87.97 α = 6.736 Gamma Federal Office of Statis‑
tics 2019U: €263.91 λ = 0.038
 Travel time to/from GP 1.5 hours L: 0.75 hours – Fixed Assumption linked to 
mean travel distanceU: 2.25 hours
 Travel time to/from 
hospital
3 hours L: 1.5 hours – Fixed Assumption linked to 
mean travel distanceU: 4.5 hours
 Time out of role due 
to ATI per treatment 
cycle in intervention 
group
0.05  daysa L: 0.025 α = 1.082 Gamma Palm et al.
U: 0.075 λ = 20.945
 Time out of role due 
to ATI per treatment 
cycle in control 
group
0.16  daysa L: 0.08 days α = 2.217 Gamma Palm et al.
U: 0.24 days λ = 13.917
 Discount rate costs 3.0% L: 0% – Fixed Eunethta
U: 6%
 Discount rate out‑
comes
3.0% L: 0% – Fixed Eunethta
U: 6%
Effectiveness and other parameters
 Number of ATIs in 
12 months prior to 
baseline
2.5 L:2 Min.: 2 Pert Palm et al.
U:3.75 Max.: 3.75
 Probability of having 
an ATI in cycle with 
intervention
0.11 L: 0.055 α = 0.323 Beta Palm et al.
U: 0.165 β = 2.629
 Probability of having 
an ATI in cycle with 
usual care only
0.21 L: 0.105 α = 1.113 Beta Palm et al.
U: 0.315 β = 4.185
 Number of expected 
ATIs in cycle with 
intervention if patient 
has an ATI
0.54 L:0.27 α = 1.736 Gamma Palm et al.
U: 0.81 λ = 3.217
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from the Association of Statutory Health Insurance Phy-
sicians is on average is €28.
We assume that there is a 2-week period out of normal 
role following surgery for adults and 1 week for children 
aged 6 to < 12 years. A mean hourly wage rate for all 
workers (full and part time) of €24.78 reported for 2019 
by the German Federal Statistical Office (Destatis) was 
used to value hourly productivity losses. From this data, 
a day out of work was also assumed to have 7.1  hours 
[25]. We also include fixed out of pocket travel costs for 
each GP consultation. In the case of days out of school, 
we assume that there are additional informal care costs 
for one parent/guardian for each child under the age of 
12 years who is unwell with an ATI. Impacts on days out 
of work or school were assumed to be the same as those 
reported in the multi-centre trial.
We assume very conservatively that all surgery for 
adults is day surgery without an overnight stay, but that 
for children aged 6–12 years the procedure involves an 
overnight stay. Typically, adults will on average take 
2  weeks and children 1  week to recover from surgery. 
Making use of data reporting average travel distance to 
GPs of 2.97 km and hospitals of 13.25 km [26] we have 
assumed that travel time to and from each GP visit would 
be 1.5  hours while for hospitals this would be 3 hours. 
We have again valued this time using the mean hourly 
rate of €24.78 for all workers. We have not included any 
direct travel costs, e.g., for public transport or petrol.
All costs are reported in 2019 Euros and both costs and 
outcomes are discounted at an annual rate of 3.0% in the 
second year of the model [27]. All costs were sourced 
in 2019 Euros with the exception of intervention costs, 
which were uprated to 2019 prices using the Campbell-
Cochrane Economics Methods Groups EPPI-Centre Cost 
Converter [28]. The model is run separately for children 
(aged 6–12 years) and adolescents and adults (aged over 
12 years).
Sensitivity analyses
A number of sensitivity analyses have been conducted 
to assess the robustness of results to underlying input 
parameters and assumptions. This includes univariate 
sensitivity analysis of specific model parameters, where 
the model is run varying the values of key parameters 
one at a time by 50% in either direction from their mean 
values in Table 1. We also identified threshold values of 
parameters at which the intervention became dominant 
or was dominated by usual care. In addition, we also 
ATI acute throat infection; GP general practitioner; C children aged 6 to < 12; AA adolescents and adults aged > 12 and up to 60; L lower; U upper
a Number of days reported as “standardized number of days” in Palm et al. i.e., number of days reported in the diary with “time out of role due to ATI” divided by the 
total number of diary days (ranging from 0 to 1, equivalent to a 0–100% scale)
Table 1 (continued)











 Number of expected 
ATIs in cycle with 
usual care only if 
patient has an ATI
0.66 L: 0.33 α = 2.089 Gamma Palm et al.
U: 0.99 λ = 3.176
 Probability of ATI being 
treated with antibiot‑
ics in intervention 
group
0.37 L:0.185 α = 3.407 Beta Palm et al.
U: 0.555 β = 5.811
 Probability of ATI being 
treated with antibiot‑
ics for ATI in usual 
care only group
0.58 L: 0.29 α = 1.939 Beta Palm et al.
U:0.87 β = 1.392
 Probability of surgery 
if 4 or more ATIs per 
year (%)
0.25 L:0.125 – Fixed Authors’ assumption
U:0.375
 Probability of all‑cause 
mortality per cycle 
(%) (C)
0.000128452 L: 0.000064226 – Fixed WHO Global Health 
Observatory 2021U: 0.000192678
 Probability of all‑cause 
mortality (%) per 
cycle (AA)
0.0007043578 L: 0.0003521789 α = 5.299 Beta WHO Global Health 
Observatory 2021U: 0.0010565367 β = 7518.025
 Probability of mortality 
following tonsillec‑
tomy (%)
0.00242348 L: 0.001938784 α = 37.407 Beta Østvoll et al. 2015
U: 0.002908176 β = 15397.71
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conducted probabilistic sensitivity analysis using Monte 
Carlo simulation modelling to determine incremental 
cost effectiveness from 10,000 replications sampled from 
within parameter distributions.
Results
In our model, for adults or children over the age of 
12 years in our base case scenario from the societal per-
spective, the incremental cost per additional ATI avoided 
in the intervention group is €156.64. The total expected 
cost per patient over the 2-year time period of the model 
in the intervention group is €297.47 compared with 
€225.64 in the usual care only group. 0.46 additional 
ATIs would be avoided per patient in the intervention 
group over this time period. Most of these costs are out 
of pocket costs to patients, except for consultations with 
general practitioners and some of the costs of antibiotics, 
which would be borne by health insurers. As Table 2 indi-
cates, some of the costs of intervention of €155.57 over 
2 years are offset mainly by a reduction in GP consulta-
tions and the travel time of individuals to attend those 
consultations. There are greater productivity losses in 
the usual care group due to time out of normal daily role. 
While use of antibiotics is lower in the adjuvant therapy 
group the very low cost of antibiotics means that this 
only has a negligible impact on costs. In our base case 
scenario there are no costs for tonsillectomy surgery. This 
is because we assume on average each patient had a his-
tory of 2.5 ATIs on entering the model, while the num-
ber of expected additional events in the usual care only 
group is 0.92 ATIs compared with 0.46 ATIs in the inter-
vention group. So, neither group ever reaches the point, 
i.e., 4 ATIs in a 2-year period, where surgery might be 
considered. When running the model for children aged 
6–12 years we find that the adjuvant therapy plus usual 
care strategy is associated with both better outcomes and 
lower costs than care as usual. This is because the costs of 
intervention are lower for children due to lower dosage 
levels.
Sensitivity analysis
One‑way sensitivity and scenario analyses
The sensitivity of the cost effectiveness ratios for the ado-
lescent and adult model to individual model parameters 
are shown as a ‘Tornado’ diagram in Figure 3. This figure 
shows the sensitivity of the results in hierarchical order 
for the ten parameters with the greatest sensitivity. The 
figure indicates that model results are most sensitive to 
changes in the probability of ATI in the usual care group. 
If the probability of at least one ATI after usual care falls 
Table 2 Summary of cost effectiveness results based on a 2‑year period
ICER incremental cost effectiveness ratio (usual care plus SilAtro-5-90 vs. usual care); CI confidence interval; ATI acute throat infection; GP general practitioner
Usual care plus SilAtro-5-90 Usual care only
Adults and adolescents over 12 years
 Adjuvant therapy 155.57 –
 Antibiotics 1.67 6.16
 GP consultations 58.91 84.57
 GP—travel time 78.20 112.27
 Tonsillectomy surgery 0.00 0.00
 Tonsillectomy surgery—travel time 0.00 0.00
 Productivity loss 3.13 22.65
Total cost (95% CI) €297.47 (€220.67, €1403.94) €225.64 (€72.83, €1905.03)
ATIs (95% CI) 0.46 (0.00, 2.22) 0.92 (0.00, 2.98)
ICER (€/ATI averted) €156.64
Children aged 6–12 years
 Adjuvant therapy 77.84 –
 Antibiotics 1.67 6.16
 GP consultations 58.91 84.57
 GP—travel time 78.20 112.27
 Tonsillectomy surgery 0.00 0.00
 Tonsillectomy surgery—travel time 0.00 0.00
 Informal care costs 3.13 22.65
Total cost (95% CI) €219.75 (€142.99, €1,519.65) €225.64 (€73.16, €2143.82)
ATIs (95% CI) 0.46 (0.00, 2.22) 0.92 (0.00, 2.95)
ICER (€/ATI averted) Dominant (intervention has lower costs and better outcomes)
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by 50% then the cost per ATI averted increases from €157 
to €2533. If the probability of ATI after usual care fell 
by 43% from 0.21 to 0.12 then the cost per ATI averted 
would be above the illustrative willingness to pay thresh-
old of €1000 threshold shown in Figure 3. Patient history 
on entering the model also has an impact. If the number 
of ATIs prior to entering the model increases to above 
3.33 then the intervention becomes cost saving. This 
is because there is then a chance of having more than 
4 ATIs, triggering the possibility of tonsillectomy sur-
gery. Varying the number of treatment cycles also has an 
impact on cost effectiveness. With just one 4-month cycle 
of treatment the cost per ATI averted would be €204.19 
compared to our base case of €157 per ATI averted with 
6 cycles of treatment. If our Markov model only had 3 
treatment cycles in a 1-year period then the cost per ATI 
averted would be slightly higher at €166. If the expected 
number of ATIs with usual care decreases by 50% then 
the cost per ATI averted increases to €1435, while a 50% 
increase would reduce the cost per ATI averted to €66. 
A 47% decrease in expected number of ATIs in the usual 
care group would also mean the notional willingness to 
pay threshold would be crossed. Figure  3 also indicates 
that the model does not appear very sensitive to all other 
parameters, including the costs of SilAtro-5-90 and days 
out of role due to ATI. Parameters such as the probabil-
ity of receiving antibiotics following ATI, likelihood of 
receiving surgery after 4 ATIs, days lost from productiv-
ity with intervention, unit costs of tonsillectomy surgery, 
travel time to and from hospital, as well as all-cause mor-
tality and tonsillectomy-surgery related mortality have a 
negligible impact on the incremental cost effectiveness 
ratio and are not shown. We have not shown the Tornado 
diagram for children as a very similar pattern was seen. 
Most notably if there was a 50% reduction of the prob-
ability of at least one ATI in the usual care group the 
intervention would no longer be cost saving, but instead 
would have a cost per ATI averted of €1208. Interven-
tion would continue to dominate usual care if the model 
only ran for 1 year, if there were just one 4-months model 
cycle it would have a cost per ATI averted of €34.59.
In addition to varying parameters by 50% in either 
direction, we also identified 5 parameters where there 
were thresholds at which the intervention would 
become dominant or be dominated compared to usual 
care. These are shown in Table  3. The threshold for 
past history of ATIs for adults and adolescents where 
the intervention dominates (has lower costs and better 
Fig. 3 Tornado diagram showing most sensitive parameters in one way sensitivity analysis for adolescents and adults model (WTP willingness to 
pay; Numbers in the parenthesis show the upper and lower bounds of the model parameters used in sensitivity analysis in Table 1; Red segments 
of bars in the diagram indicate increasing values of each parameter and blue segments decreased values. Values to the right of our mean expected 
value of the ICER of €156.64 per ATI averted indicate a reduction in cost effectiveness of intervention relative to usual care, while those to the left 
indicate an improvement in cost effectiveness.)
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outcomes) is 3.33 ATIs. For the model for children, 
even without any past ATIs, the reduction in expected 
number of ATIs means that the intervention is always 
dominant. For children the intervention group no 
longer dominates usual care when the probability of 
ATI increases to 0.118, equivalent to a 42% reduction 
in ATI. For children only, the intervention is cost saving 
until the expected number of ATIs in children experi-
encing ATI in any cycle reduces from 0.66 to 0.52. For 
children if the model only had 2 treatment cycles, cov-
ering an 8 month-time period rather than 2 years then 
the intervention would no longer dominate usual care. 
Finally, for both adults and children if the cost of SilA-
tro-5-90 adjuvant therapy was below €14.49 then the 
intervention would be dominant. Compared to base 
case, for the intervention to be dominant for adults and 
adolescents would mean the costs of adjuvant therapy 
would have to fall by 46%.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was also performed, 
using Monte Carlo simulation with 10,000 replications 
sampled from the distributions for adults presented in 
Table  2. The cost effectiveness plane for the adults and 
adolescent model for incremental cost effectiveness of 
usual care plus adjuvant therapy versus usual care only is 
shown in Fig. 4, while the results for the model for chil-
dren are given in Fig. 5.
For adults and adolescents, the distribution of the 
simulations indicates that SilAtro-5-90 adjuvant therapy 
in addition to usual care would avert ATIs at lower costs 
in 3157 (32%) of simulations. In a further 4493 (45%) of 
Table 3 Threshold analysis
ATI acute throat infection
Parameter description Adolescents/adults Child aged 6–12
Number of recurrent ATIs in 12 months prior to 
treatment (base case 2.5)
3.33 ATIs: intervention becomes dominant No threshold. Intervention dominant in all scenarios
Probability of ATI after intervention No threshold Intervention no longer dominates where probability 
of ATI rises to 0.118
Reducing the expected number of ATIs in the con‑
trol group in any one cycle (base case 0.66)
No threshold Intervention no longer dominates when expected 
number of ATIs falls to 0.52
Number of treatment cycles (base case 6) No threshold Intervention no longer dominates when 2 or fewer 
treatment cycles
Cost of SilAtro‑5‑90 (base case €13 and €26 per 
cycle for children and adults)
Intervention becomes dominant when 
cost falls to €14.48
Intervention no longer dominates when costs 
increase to €14.49
Fig. 4 Cost effectiveness plane of the adults and adolescent model for incremental cost effectiveness of usual care plus adjuvant therapy versus 
usual care alone. The elliptical circle includes 95% of the simulations in the model (ATI acute throat infection)
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simulations adjuvant therapy would avert ATIs but at 
higher cost. Society would then have to consider whether 
it would be willing to pay these extra costs for the ATI 
averted. This is due to the extra costs of surgery incurred 
by some individuals who experience more than 4 ATIs 
in the model. The simulation also suggests there is a 23% 
chance that the intervention would be inferior to usual 
care only with higher costs and fewer ATIs averted. When 
running probabilistic sensitivity analysis on the model for 
children aged 6–12 years, from a societal perspective in 
4996 simulations (50%) adjuvant therapy plus usual care 
is cost saving with additional ATI events averted at lower 
cost. In another 2615 simulations (26%) intervention plus 
usual care is more effective but also more expensive than 
usual care. The simulation model suggests there is a 23% 
chance that the intervention would be inferior to control 
with higher costs and fewer ATIs averted.
We also constructed cost effectiveness acceptability 
curves for both of these models based on the probabil-
istic sensitivity analyses. These curves indicate the like-
lihood that an intervention is cost effective at different 
willingness to pay levels. For adults and adolescents this 
indicates that for a willingness to pay of more than €230 
per ATI averted adjuvant therapy plus usual care has 
a greater chance of being cost effective than usual care, 
with this rising to a 65% chance of being cost effective at 
a hypothetical willingness to pay level of €1000 (Fig. 6). 
For children, even if their parents/guardians are unwill-
ing to pay anything per ATI averted, adjuvant ther-
apy plus usual care still has a 51% chance of being cost 
effective, with this rising to a 71% chance of being cost 
effective at a hypothetical willingness to pay threshold of 
€1000 (Fig. 7).
Discussion
Tonsillitis is a common problem in the primary care sec-
tor, which in cases of a bacterial origin is treated with 
antibiotics. For an integrative patient care approach, 
standardised, safe, and cost-effective treatment strate-
gies are essential. While several authors have dealt with 
the question of cost-effectiveness of tonsillitis treatment, 
in particular concerning tonsillectomy [29, 30], integra-
tive approaches such as homeopathy so far have not been 
analysed with respect to cost-effectiveness in tonsilli-
tis, although there is a growing demand to conduct cost 
effectiveness studies in the field of Integrative medicine 
to inform decision making [31].
The present study for the first time analysed the cost-
effectiveness of SilAtro-5-90 as an adjuvant therapy to 
usual care for patients with mild to moderate acute or 
recurrent tonsillitis based on a previously published trial. 
Our findings suggest that the intervention in our base 
case scenario indicates a cost of €156.64 per ATI averted. 
Policy makers need to think of how much they would be 
willing to pay to avert ATIs; at minimum, our model sug-
gests for adults this must be more than €230 to be more 
favourable than usual care. In the case of children aged 6 
to < 12 years, from a societal perspective adjuvant ther-
apy appears cost saving with both better outcomes and 
lower costs than usual care only. In the case of children 
Fig. 5 Cost effectiveness plane of the children model for incremental cost effectiveness of usual care plus adjuvant therapy versus usual care alone. 
The elliptical circle includes 95% of the simulations in the model (ATI acute throat infection)
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in half of the Monte Carlo simulations, it was shown that 
SilAtro-5-90 therapy averts ATIs at lower costs.
Our analyses also suggest that the more accurately the 
use of adjuvant therapy can be targeted at people with a 
history of recurrent tonsillitis, the more the cost effec-
tiveness of the intervention is strengthened, as interven-
tion may potentially help avoid surgical intervention. We 
therefore examined how differences in previous history 
of recurrent tonsillitis impact on the cost effectiveness 
of the intervention. In our base case scenario no indi-
viduals would meet the criteria for tonsillectomy surgery 
as no individuals would experience 4 or more ATIs in 
2  years. However if intervention were targeted to those 
with a higher level of past ATI then there are additional 
potential benefits if tonsillectomy surgery can be avoided. 
In our sensitivity analysis, where we assume that there 
would be a 25% chance of being referred for tonsillec-
tomy surgery after 4 recurrent events, if an individual 
Fig. 6 Cost effectiveness acceptability curve: adolescents and adults
Fig. 7 Cost effectiveness acceptability curve: children
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has on average a history of 3.33 events prior to entering 
the model (rather than our expected average of 2.5 prior 
ATIs) then the intervention group will have both lower 
costs and better outcomes than the care as usual group. 
In the multi-country trial of SilAtro-5-90 20% of individ-
uals entered the study with a history of 4 or more ATIs 
[16]. For this type of patient,  SilAtro-5-90 should be con-
sidered as a promising adjuvant treatment option as it 
may help contribute to the chance of avoiding expensive 
tonsillectomy surgery, which is the most common con-
servative treatment option, in case of frequent episodes 
of ATIs. While surgery is generally successful, each sur-
gery bears a small risk of pain and side effects, as well as 
mortality, all of which could have a negative impact on 
society in terms of loss of productivity and costs for the 
surgery.
Besides benefits to individual patients of having fewer 
ATIs and in the long term potentially avoiding sur-
gery, there are potential spill-over benefits beyond the 
patient to the health care system and society as every ATI 
averted reduces the use of antibiotics, helping to address 
the threat of AMR. These benefits are not captured in 
our economic model. All of these potential advantages 
depend on patients making use of the intervention. The 
cost of SilAtro-5-90 therapy is borne by patients rather 
than health insurers as homeopathic medicines are over 
the counter medications. Ultimately, patients will need to 
make a judgement as to whether they are prepared to pay 
€13.45 (adults) or €6.73 (children) per month of treat-
ment for the additional ATIs averted. The costs appear 
relatively modest as they fall well within reported expen-
ditures for homeopathic remedies (ranging from €3.70 to 
€124.54 per month) [8], although as with all out of pocket 
medications there will be inequalities in access and 
uptake linked to levels of income.
Limitations
Many of our Markov model parameters are drawn from 
a single multi-county open label trial where participants 
were only followed up for 12 months. The method of the 
clinical trial is clearly described in the original publica-
tion [16], the study diagnoses were medically confirmed, 
and the robustness of the results were underlined by sen-
sitivity analysis. To date, however, the clinical trial has 
not been repeated, nor has the mechanism of action of 
SilAtro-5-90 been researched. While we have undertaken 
extensive sensitivity analyses to mitigate for uncertainty 
in model parameters, more trials are needed to see if 
these results from a single study can be replicated, both 
in trials and in pragmatic studies in real world condi-
tions. Moreover, differences in health system structures, 
attitudes towards complementary therapies and real-
world practice between countries, as potentially patterns 
of effectiveness and antibiotic prescribing behaviour may 
vary across settings.
Another limitation is a lack of separate published data 
on the ATIs averted in children aged under 12 years com-
pared to impacts in adults and adolescents. The published 
trial paper indicated that age did not have a significant 
impact on outcomes so we have assumed that effective-
ness rates are the same regardless of age. Nevertheless, 
there might be differences in effect that we are unaware 
of; potentially there might also be differences by gender. 
Future trials need to assess the effectiveness and cost-
effectiveness of adjuvant therapy for different age groups, 
genders and other population groups in different country 
settings. If economic analyses can be conducted prospec-
tively alongside trials so that there is access to individual 
patient level data future studies might also consider look-
ing at longer term cost effectiveness using discrete event 
simulation modelling with time to ATI event rather than 
the likelihood of experiencing an ATI event being the pri-
mary outcome. There is also a need to assess whether the 
uptake and sustained use of adjuvant therapy outside of 
the conditions of a controlled trial can be replicated in 
real-world settings, particularly as patients would have to 
pay out-of-pocket for adjuvant therapy. This is also some-
thing that could be considered in future implementation 
studies in Germany and other settings.
Another limitation is the lack of published data on 
quality of life associated with ATIs using a validated 
quality of life scale such as the EUROQOL EQ-5D that 
is used in health economic analysis [32, 33] or even a 
specific assessment instrument such as the Sore Throat 
Quality of Life Questionnaire (STQoL) [34] to get a more 
differentiated picture of the impact of the intervention. 
We have noted that there is no accepted willingness to 
pay threshold for the avoidance of ATIs. If we had EQ-5D 
quality of life data we could have calculated the cost per 
QALY gained. Established cost effectiveness thresholds 
could then have been used; this would have allowed com-
parisons to be made between investment in different 
measures not only to tackle ATI, but any other potential 
use of health care resources. We also considered using 
published utility estimates associated with ATIs to esti-
mate QALY gains to overcome this limitation, but were 
unable to source any utility values for ATIs suggesting 
that there have been very few economic evaluations for 
interventions to reduce ATIs (other than evaluations of 
tonsillectomy) [29]. We are however aware of one trial 
and economic evaluation completed in 2020, but as yet 
unpublished, of tonsillectomy in adults in the UK that 
has collected quality of life data on ATIs; this potentially 
will provide utility values to inform future modelling 
studies [35]. In saying that, one of the challenges, even 
with the use of QALYs thresholds is that they reflect the 
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willingness of health care funders to cover the costs of 
any treatment. However, in this case much of the imme-
diate cost and cost offsets associated with treatment or 
usual care are borne by patients and their families rather 
than health care systems.
Our model estimates of economic impact may how-
ever be conservative; we have not included any costs for 
hospitalization for acute tonsillitis, nor did we include 
the costs of complications associated with surgery, with 
a Canadian study indicating that 3% of children are 
readmitted within 30  days [36]. In the model, we have 
assumed that all tonsillectomies are day procedures for 
adults and have just one night’s stay for children; proce-
dures can still be performed on an inpatient basis, with 
several days spent in hospital. For children we have also 
conservatively assumed that only one parent gives up 
time for their usual activities to accompany their child to 
any surgical procedure, yet 64% of children in a previous 
Belgian analysis for 275 children who underwent tonsil-
lectomy were accompanied by both parents [30]. While 
this would not affect our base case findings, as no indi-
viduals would meet the criteria for tonsillectomy surgery, 
it would affect the likelihood of being cost effective in our 
probabilistic sensitivity analysis.
With respect to the treatment, our analyses are also 
limited by the fact that only the cost scenario for penicil-
lin V was calculated. We have not considered the impact 
of penicillin allergies where other, possibly more expen-
sive antibiotics would then be necessary (e.g., Macrolides 
like Clindamycin). The same limitation is given for sur-
gical procedures: tonsillectomy was assumed for sur-
gery, while other procedures like tonsillotomy, albeit far 
less common in adults and mostly applied in children, 
have not been considered as a surgical procedure in our 
analysis.
Integrative medicine and cost effectiveness
Papers often claim that integrative medicine is poten-
tially cost-effective compared to conventional treat-
ment [37, 38]. Even if evidence for this claim is still 
weak, particularly in the field of homeopathy [39], some 
encouraging results have recently been published. In a 
prospective observational study, add-on homeopathic 
treatment in routine care seemed to be cost effective 
from an insurer perspective in terms of additional costs 
per quality-adjusted life year for 3 out of the 5 assessed 
chronic diseases: migraine or headache, atopic dermati-
tis and depression [40]. From a health services perspec-
tive, a systematic review of economic evaluations found 
one study that according to the authors compared “usual 
care to usual care plus access to multiple licensed CIM 
practitioners” [41]. In this review, the authors thus rec-
ommend that further studies should at least include one 
arm of usual care and should contain sensitivity analyses. 
Finally, they state that “more consideration be given to 
modelling as a method to estimate economic outcomes 
for existing effectiveness trial results, to increase the reli-
ability of results”. The present economic analysis fully 
takes up these recommendations and presents a full eco-
nomic analysis in the field of primary care which is the 
major setting of homeopathy.
Conclusions
This paper provides a real-world health economic pic-
ture of homeopathic treatment of recurrent tonsillitis in 
primary care indicating the importance of considering 
homeopathic treatment for this indication from a socio-
economic perspective. It also underlines the possible 
role homeopathy can play as adjuvant therapy in the “no-
antibiotics” or “delayed antibiotics” strategy for the treat-
ment of RTI, thereby contributing to combating AMR. 
Additionally, the treatment with SilAtro-5-90 can avoid 
tonsillectomy with its inconveniences for patients due 
to surgery and costs for society (direct for the surgery 
and indirect, for e.g., absence of work). Further studies 
should take up this approach for a deeper understand-
ing of potential fields of cost effectiveness, not limited to 
homeopathic primary care but for the full spectrum of 
integrative primary care.
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